National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Dictionary of Cancer Terms
In EnglishEn español
Page Options
Print This Page  Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
In EnglishEn español

Recentin (reh-SEN-tin)

 A substance being studied in the treatment of some types of cancer. Recentin blocks the growth of new blood vessels needed for tumors to grow and may kill cancer cells. It is a type of angiogenesis inhibitor and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. Also called AZD2171 and cediranib.



Previous Definitions:RAV12, ravuconazole, RBC, rebeccamycin, rebeccamycin analog
Next Definitions:receptor, recombinant, recombinant adenovirus-p53, recombinant fowlpox-CEA-MUC-1-TRICOM vaccine, recombinant fowlpox-TRICOM vaccine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov